Related Experiment Video
Updated: Jan 16, 2026
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Material Matters: A Systematic Review and Meta-Analysis of the Effectiveness of Different Embolic Agents in Middle
Mitesh Gupta1, Abhisek Saha1, Abhishek Gupta1
1Department of Intervention Radiology, National Institute of Medical Sciences, Jaipur, India.
Purpose:
To compare the effectiveness and safety of different embolizing agents used in middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematoma.
Materials And Methods:
A literature search of PubMed, Cochrane Library, Scopus, and Google Scholar (up to 2024) included studies reporting MMAE outcomes for chronic subdural hematoma (cSDH). Study quality was evaluated using the Joanna Briggs Institute and Risk of Bias 2 (RoB 2) tools. Pooled data were analyzed with random-effects models, with heterogeneity assessed via the I2 statistic. Statistical significance was set at P < .05.
Results:
Of 997 articles screened, 33 studies (2013-2024) with 1,818 patients (mean age, 74.2 years [SD ± 11]; median follow-up, 3 months) were included. The pooled recurrence rate after MMAE was 0.07 (95% confidence interval, 0.05-0.10). By embolic agent, recurrence rates were the following: (a) polyvinyl alcohol (PVA), 0.07; (b) n-butyl cyanoacrylate (nBCA), 0.05; and (c) ethylene vinyl alcohol copolymer (EVOH), 0.07. Periprocedural complication rates were low: PVA, 0.02; nBCA, 0.01; EVOH, 0.00; and overall rate, 0.01. Favorable clinical and radiologic outcomes were observed in 81% and 84% of cases, respectively.
Conclusions:
MMAE is effective for cSDH, offering low recurrence and complication rates with favorable clinical and radiologic outcomes. All embolic agents demonstrated promising effectiveness and safety profiles.
